<!DOCTYPE html>
<html>
<head>
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="description" content="My name is Michael Bernauer, I'm a 4th year PharmD student at  the University of New Mexico College of Pharmacy. In addition to pharmacy, my interests include programming (R, Python, Julia, MySQL), machine learning, data analysis, health informatics, pharmacovigilance, and data mining.
">
  <meta name="keywords" content="bernauer, michael l bernauer, michael, UNM, pharmacy, informatics">
  <title>Michael L. Bernauer</title>
  <link rel="shortcut icon" type="image/x-icon" href="../img/portrait_crop.png"/>
  <!-- link type="text/css" rel="stylesheet" media="all" href="../../css/reset.css"/>-->
  <link type="text/css" rel="stylesheet" media="all" href="../../css/default.css"/>
  <link type="text/css" rel="stylesheet" media="all" href="../../css/syntax.css"/>
  <script type="text/javascript" src="../../js/smoothscroll.js">
  <script type="text/javascript" src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.3/jquery.min.js"></script>
  <link href='http://fonts.googleapis.com/css?family=Cambo' rel='stylesheet' type='text/css'>

  <!-- Used to display interactive particle banner -->
  <!--
  <script language="javascript" src="/js/p5.js"></script>
  <script src="/banner/sketch.js"></script>
  -->
</head>

<body>
<div id="header">
  <div class="transparent">
    <div class="nav">
      <ul>
        <li><a href="http://mlbernauer.github.io/#home">Michael L. Bernauer</a></li>
        <li><a href="http://mlbernauer.github.io/#about">About</a></li>
        <li><a href="http://mlbernauer.github.io/#projects">Projects</a></li>
        <li><a href="http://mlbernauer.github.io/assets/2015_bernauer_curriculum_vitae.pdf">Curriculum Vitae</a></li>
        <li><a href="/pages/downloads">Downloads</a></li>
        <li><a href="/pages/slides">Slides</a></li>
        <li><a href="#contact">Contact</a></li>
      </ul>
    </div>
  </div>
</div>

<div class="page_container">
  <div class="content">
    <h1></h1>
    <div class="deets">
      <span class="date"></span>
    </div>
    <p><em>by <a href="http://mlbernauer.com">Michael L. Bernauer</a></em></p>

<h1 id="vte-treatment">VTE Treatment</h1>

<h2 id="acute-dvt-pe-general-management">Acute DVT/PE general management</h2>

<h3 id="general-2-drug-therapy">General 2 drug therapy</h3>

<ul>
<li>Rapid anticoagulation with <strong>LMWH</strong>, <strong>IV UFH</strong>, <strong>SQ UFH</strong> with <strong>warfarin</strong> is necessary

<ul>
<li><strong>LMWH</strong> or <strong>fondaparinux</strong> preferred over <strong>IV UFH</strong> or <strong>SQ UFH</strong>

<ul>
<li>Once daily <strong>LMWH</strong> is preferred to twice daily <strong>LMWH</strong></li>
<li>Use caution in old age, poor renal function, post-surgical patients as once daily
dosing causes anticoagulation spike and may increase risk of bleeding</li>
<li>Consider BID dosing in patients with high clot burden (saddle embolism)</li>
</ul></li>
<li>Overlap parenteral anticoag with warfarin for a minimum of 5 days and until INR is 2-3 for at
least 24 hours.

<ul>
<li>If INR &gt; 3 prior to day 5; consider decreasing <strong>warfarin</strong> dose unless and continuing
parenteral unless there is risk of bleed.</li>
<li>If INR &gt; 3 prior to day 5 <strong>and</strong> there is bleed; consider discontinuing parenteral agent
and continuing only <strong>warfarin</strong>

<ul>
<li>The reason for discontinuation of parenteral agent must be documented!</li>
</ul></li>
</ul></li>
</ul></li>
</ul>

<h3 id="direct-oral-anticoagulant-doac-single-drug-therapy">Direct Oral Anticoagulant (DOAC) Single Drug Therapy</h3>

<ul>
<li><strong>Rivaroxaban</strong> and <strong>apixaban</strong> are both FDA approved for:

<ul>
<li>Treatment of DVT/PE</li>
<li>Reducing risk of recurrent DVT/PE after initial anticoagulant therapy.</li>
</ul></li>
<li>Can be used without initial parenteral lead-in period.</li>
<li>Should not be overlapped with parenteral agent due to PK similarities</li>
<li>Inpatient anticoag services are required for use of <strong>rivaroxaban</strong>/<strong>apixaban</strong> for acute/recurrent 
VTE</li>
</ul>

<h3 id="criteria-for-doac">Criteria for DOAC</h3>

<ul>
<li>Need based on acute VTE or recurrent VTE prevention</li>
<li>Patient able to afford drug; insurance, out of pocket, patient assistance</li>
<li>Creatinine clearance &gt; 30 mL/min</li>
<li>Not on CYP3A4 P-</li>
</ul>

  </div>
</div>
<div>
  <!--CONTACT-->
<div id="contact">
  <div class="beginning">
    <h2>contact</h2>
  </div>
  <div class="wrap-one">
    <div class="social">
      <p class= "about">If you want to get in touch, email is probably best. But you have options.</p>
      <a href="mailto:mlbernauer@gmail.com" class="mailicon" title="mail"></a>
      <a href="http://twitter.com/mlbernauer" class="twittericon" title="twitter"></a>
      <a href="http://www.facebook.com/mbernauer" class="facebookicon" title="facebook"></a>
      <a href="https://github.com/mlbernauer" class="githubicon" title="github"></a>
      <a href="https://www.flickr.com/photos/mlbernauer/" class="flickricon" title="flickr"></a>
    </div>
  </div>
</div>

  <!--FOOTER-->
<div id="footer"></div>

</div>
</body>
</html>
